Clinical Focus
TRPV Pharma is a specialty pharmaceutical company striving to bring to clinic the first phase of compounds based on the 2021 Noble Prize winning discovery of Transient Receptor Potential Vanilloid channels.
Our focus is on bringing together decades of preclinical, clinical and regulatory experience to accelerate drug development in the broad cardiovascular space by leveraging established compounds active on TRP channels through repurposing pathways and new compounds through preclinical and early phase studies.
Our lead compound has been studied by Dr. Rubinstein's laboratory and is set to initiate phase 1b/2a trials in early 2023.
Current Pipeline
Our pipeline strategy is based on the broad applicability of TRPV channel modulation.
We believe we are at the leading edge in the development of a new class of compounds and delivery systems that will revolutionize the management of cardiovascular diseases, as well as renal, neurologic, hematologic and oncologic related conditions.